Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;126(1):179-81.
doi: 10.1016/j.jaci.2010.03.035.

Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence

Martin M Crane, Cindy Ma Chang, Monica G Kobayashi, Peter F Weller

Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence

Martin M Crane et al. J Allergy Clin Immunol. 2010 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

Figures

FIG. 1
FIG. 1
Age-specific incidence per 100,000 for myeloproliferative HES/CEL in SEER, 2001 to 2005, by sex.
See this image and copyright information in PMC

References

    1. Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:333–55. - PubMed
    1. Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006;117:1292–302. - PubMed
    1. Klion AD. Approach to the therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:551–60. - PubMed
    1. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, editors. SEER cancer statistics review, 1975–2004. National Cancer Institute; Bethesda, Md: 2007. Available at: http://seer.cancer.gov/csr/1975_2004/
    1. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–14. - PubMed

Substances